Veracyte annual ebitda
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Veracyte EBITDA Growth & History (VCYT)
Veracyte's calculated EBITDA was $79.2M for fiscal 2025.
View full Veracyte company overviewVeracyte annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $79.2M | $39.6M | +99.97% |
| 2024 | 2024-12-31 | $39.6M | $98.2M | — |
| 2023 | 2023-12-31 | −$58.6M | −$43.5M | — |
| 2022 | 2022-12-31 | −$15.2M | $47.2M | — |
| 2021 | 2021-12-31 | −$62.3M | −$34.9M | — |
| 2020 | 2020-12-31 | −$27.4M | −$16.4M | — |
| 2019 | 2019-12-31 | −$11.0M | $7.3M | — |
| 2018 | 2018-12-31 | −$18.3M | $4.4M | — |
| 2017 | 2017-12-31 | −$22.7M | $2.6M | — |
| 2016 | 2016-12-31 | −$25.3M | $5.9M | — |
| 2015 | 2015-12-31 | −$31.2M | −$3.4M | — |
| 2014 | 2014-12-31 | −$27.8M | −$5.7M | — |
| 2013 | 2013-12-31 | −$22.2M | −$4.0M | — |
| 2012 | 2012-12-31 | −$18.2M | −$3.6M | — |
| 2011 | 2011-12-31 | −$14.7M | — | — |
Veracyte quarterly ebitda
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27.8M | $27.6M | +12487.33% |
| Q1 2026 | 2026-03-31 | $28.1M | $19.8M | +239.66% |
| Q4 2025 | 2025-12-31 | $42.5M | $32.1M | +307.49% |
| Q3 2025 | 2025-09-30 | $28.2M | $10.3M | +57.65% |
| Q2 2025 | 2025-06-30 | $221,000 | −$10.1M | −97.86% |
| Q1 2025 | 2025-03-31 | $8.3M | $7.3M | +785.01% |
| Q4 2024 | 2024-12-31 | $10.4M | $39.6M | — |
| Q3 2024 | 2024-09-30 | $17.9M | $42.3M | — |
| Q2 2024 | 2024-06-30 | $10.3M | $11.5M | — |
| Q1 2024 | 2024-03-31 | $934,000 | $4.8M | — |
| Q4 2023 | 2023-12-31 | −$29.2M | −$30.3M | — |
| Q3 2023 | 2023-09-30 | −$24.4M | −$21.1M | — |
| Q2 2023 | 2023-06-30 | −$1.2M | $3.0M | — |
| Q1 2023 | 2023-03-31 | −$3.8M | $4.9M | — |
| Q4 2022 | 2022-12-31 | $1.1M | $7.1M | — |
| Q3 2022 | 2022-09-30 | −$3.4M | $7.2M | — |
| Q2 2022 | 2022-06-30 | −$4.2M | −$1.3M | — |
| Q1 2022 | 2022-03-31 | −$8.7M | $34.2M | — |
| Q4 2021 | 2021-12-31 | −$5.9M | $118,000 | — |
| Q3 2021 | 2021-09-30 | −$10.5M | −$8.5M | — |
| Q2 2021 | 2021-06-30 | −$3.0M | $6.1M | — |
| Q1 2021 | 2021-03-31 | −$42.9M | −$32.6M | — |
| Q4 2020 | 2020-12-31 | −$6.0M | $869,000 | — |
| Q3 2020 | 2020-09-30 | −$2.1M | −$1.3M | — |
| Q2 2020 | 2020-06-30 | −$9.1M | −$6.9M | — |
| Q1 2020 | 2020-03-31 | −$10.2M | −$9.1M | — |
| Q4 2019 | 2019-12-31 | −$6.9M | −$4.8M | — |
| Q3 2019 | 2019-09-30 | −$796,000 | $2.5M | — |
| Q2 2019 | 2019-06-30 | −$2.2M | $2.8M | — |
| Q1 2019 | 2019-03-31 | −$1.1M | $6.9M | — |
| Q4 2018 | 2018-12-31 | −$2.1M | $3.0M | — |
| Q3 2018 | 2018-09-30 | −$3.3M | $2.1M | — |
| Q2 2018 | 2018-06-30 | −$4.9M | $737,000 | — |
| Q1 2018 | 2018-03-31 | −$8.0M | −$1.4M | — |
| Q4 2017 | 2017-12-31 | −$5.0M | −$2.3M | — |
| Q3 2017 | 2017-09-30 | −$5.4M | −$1.4M | — |
| Q2 2017 | 2017-06-30 | −$5.7M | $3.9M | — |
| Q1 2017 | 2017-03-31 | −$6.6M | $2.4M | — |
| Q4 2016 | 2016-12-31 | −$2.8M | $4.6M | — |
| Q3 2016 | 2016-09-30 | −$4.0M | $4.3M | — |
| Q2 2016 | 2016-06-30 | −$9.6M | −$1.1M | — |
| Q1 2016 | 2016-03-31 | −$9.0M | −$1.8M | — |
| Q4 2015 | 2015-12-31 | −$7.3M | $378,000 | — |
| Q3 2015 | 2015-09-30 | −$8.2M | −$723,000 | — |
| Q2 2015 | 2015-06-30 | −$8.4M | −$2.1M | — |
| Q1 2015 | 2015-03-31 | −$7.2M | −$890,000 | — |
| Q4 2014 | 2014-12-31 | −$7.7M | −$2.2M | — |
| Q3 2014 | 2014-09-30 | −$7.5M | −$1.7M | — |
| Q2 2014 | 2014-06-30 | −$6.3M | −$1.1M | — |
| Q1 2014 | 2014-03-31 | −$6.3M | −$615,000 | — |
| Q4 2013 | 2013-12-31 | −$5.5M | — | — |
| Q3 2013 | 2013-09-30 | −$5.8M | — | — |
| Q2 2013 | 2013-06-30 | −$5.2M | — | — |
| Q1 2013 | 2013-03-31 | −$5.7M | — | — |
Veracyte ebitda trends
Over the last five fiscal years, Veracyte's ebitda increased from −$27.4M to $79.2M, a change of $106.6M. The latest reported quarter, Q2 2026, shows $27.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Veracyte source filings ↗Community posts
New Decipher analysis links genomic scores to benefit from added hormone therapy
Veracyte ($VCYT) reported a retrospective analysis of samples from 395 participants in a randomized Phase III prostate-cancer trial. Patients with intermediate or high Decipher genomic scores had an eight-percentage-point reduction in ten-y ...
